{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-009499","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.028295+00:00","generated_at":"2026-06-15T02:12:18.120564+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bio-Path Q1 net loss $5.3M ($0.66/share); cash burns to $6.7M; clinical milestones Q2/3","bullets":["Net loss $5.3M ($0.66/share) vs $3.4M ($0.47) Q1 2022; R&D spend doubled to $4.0M.","Cash $6.7M at Mar 31, down from $10.4M Dec 31; net cash used in ops $3.7M.","BP1001-A solid tumor trial initial cohort completion/data readout expected mid-2023.","BP1002 relapsed/refractory AML cohort readout expected mid-2023.","Prexigebersen Phase 2 AML: two cohorts exceeded min efficacy for expansion; interim analyses start Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-009499","json":"https://secwatch.observer/filing/0001558370-23-009499.json","markdown":"https://secwatch.observer/filing/0001558370-23-009499.md","text":"https://secwatch.observer/filing/0001558370-23-009499.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837023009499/0001558370-23-009499-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837023009499/bpth-20230512x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:12:18.120564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06712112bd04191d3d99a61e46e802932e078627","claim":"BIO-PATH HOLDINGS, INC. reported first quarter ended March 31, 2022 results: net income a net loss of $3.4 million, or $0.47 per share.","evidence_excerpt":"The Company reported a net loss of $5.3 million, or $0.66 per share, for the three months ended March 31, 2023, compared to a net loss of $3.4 million, or $0.47 per share, for the three months ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133818/000155837023009499/0001558370-23-009499-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2022"},{"label":"Net income","value":"a net loss of $3.4 million, or $0.47 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"aff5673be41cc20a1bf84dd9fff9955ac204ed66","claim":"BIO-PATH HOLDINGS, INC. reported first quarter ended March 31, 2023 results: net income a net loss of $5.3 million, or $0.66 per share.","evidence_excerpt":"The Company reported a net loss of $5.3 million, or $0.66 per share, for the three months ended March 31, 2023, compared to a net loss of $3.4 million, or $0.47 per share, for the three months ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133818/000155837023009499/0001558370-23-009499-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"a net loss of $5.3 million, or $0.66 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}